Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at ...

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

These peptides (T-cell epitopes ... Focusing on a limited set of antigens is also relevant to cancer vaccination in which tumour cells or lysates may contain predominantly normal self-proteins ...

Therapeutics is pleased to showcase its survival and clinical benefit data in MBC patients, including those with CNS ...

BriaCell successfully identified immunogenic (i.e. immune system activating) peptides in patients treated with Bria-IMT™, a cell-based cancer vaccine, and showed Bria-IMT™'s ability to produce a ...

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

Interesting targets for peptide vaccination have been defined including Wilms tumor gene 1 ... For the three aforementioned antigens, more and more epitope peptides have been defined.

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.

However, the effectiveness of these therapies depends on the distribution of cancer-associated antigens across the tumor. Tumors with uniform antigen expression respond well to ICB therapy, while ...